Drugs that prevent blood clots may protect organs during transplantation

When an organ is transplanted from a donor to a recipient, there is a period of time when the organ is deprived of normal blood flow. While this in itself can cause tissue damage, additional damage may also occur when blood flow is restored to the organ due to a high risk of blood clotting.

Investigators led by Thierry Hauet, MD, PhD, of the Institut National de la Santé et de la Recherche Médicale (INSERM), the University of Poitiers, and the Centre Hospitalier Universitaire (CHU) de Poitiers, in France, wondered whether anticoagulants or "blood thinners" might help protect transplant organs against these effects. The team tested the potential of fondaparinux in an experimental model of kidney transplantation. Use of the anticoagulant was linked with improved kidney function both immediately after transplantation and several months later.

"People die every day from the lack of available organs. This study demonstrates the benefits of anticoagulation therapy using new and original drugs at the time of organ collection," said Dr. Hauet. "Such therapy could augment the pool of available organs and allow for the safe use of marginal organs, which have characteristics associated with poorer outcomes or come from donors with medical complexities."

Such an anticoagulation strategy could be an important addition to current transplant protocols to limit tissue damage and improve outcomes in patients receiving kidney, liver, pancreas, lung, heart, and other organ transplants.